Fly News Breaks for December 9, 2016
EW
Dec 9, 2016 | 08:09 EDT
Leerink analyst Danielle Antalffy lowered her price target for Edwards Lifesciences to $110 from $130 to reflect a recent multiple pullback across MedTech. The analyst believes the company's 2017 guidance will prove to be a "base-case" scenario, and has a high level of confidence that Edwards Lifesciences is well-positioned for outperformance throughout the year. She reiterates an Outperform rating on the shares.
News For EW From the Last 2 Days
EW
Apr 15, 2024 | 08:08 EDT
RBC Capital analyst Shagun Singh raised the firm's price target on Edwards Lifesciences to $101 from $95 and keeps an Outperform rating on the shares as part of a broader research note previewing Q1 earnings for Medical Devices. The sector fundamentals are "flashing positive signals" and the firm is expecting strong results, the analyst tells investors in a research note. RBC adds that sentiment on the stock is mostly positive heading into the Q1 earnings season as TAVR trends appear to be steady and as investors focus on the multi-billion TMTT - or Transcatheter Mitral and Tricuspid Therapies - opportunity that is yet to be meaningfully factored into estimates.